Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report)’s stock price hit a new 52-week low during trading on Thursday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 408000 shares traded. The stock had previously closed at C$0.02.
Aequus Pharmaceuticals Stock Performance
The company has a quick ratio of 0.46, a current ratio of 0.07 and a debt-to-equity ratio of 138.88. The firm has a 50 day moving average of C$0.01 and a 200-day moving average of C$0.02. The company has a market cap of C$663,150.00, a P/E ratio of -0.50 and a beta of -0.02.
Aequus Pharmaceuticals (CVE:AQS – Get Free Report) last announced its quarterly earnings results on Thursday, August 29th. The company reported C($0.01) EPS for the quarter. The firm had revenue of C$0.16 million during the quarter. As a group, sell-side analysts anticipate that Aequus Pharmaceuticals Inc. will post -0.1 EPS for the current fiscal year.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Read More
- Five stocks we like better than Aequus Pharmaceuticals
- NYSE Stocks Give Investors a Variety of Quality Options
- Why Palo Alto Networks’ Multi-Year Uptrend Is Far From Over
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3 Rock-Solid Buying Opportunities in the Market Right Now
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- TJX Companies Stock Poised to Hit a New High This Year
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
